Enhancing Cognitive Training Through Exercise Following a First Schizophrenia Episode



Status:Recruiting
Conditions:Schizophrenia, Psychiatric
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:18 - 45
Updated:2/22/2018
Start Date:September 2016
End Date:June 2021
Contact:Joseph Ventura, Ph.D.
Email:JVentura@mednet.ucla.edu
Phone:310-206-3142

Use our guide to learn which trials are right for you!

This is a confirmatory randomized controlled trial of the efficacy of a novel intervention
combining neuroplasticity-based cognitive training with aerobic exercise, compared to the
same systematic cognitive training alone. Treatment occurs for 6 months after randomization,
with a followup assessment at 12 months. The investigators hypothesize that combining
neuroplasticity-based computerized cognitive training and neurotrophin-enhancing physical
exercise will produce neurotrophin increases and cognitive and functional improvements, even
relative to cognitive training alone. The investigators target the period shortly after a
first episode of schizophrenia to maximize the generalization of cognitive improvement to
functional outcome, before chronic disability is established.

The Cognitive Training and Exercise intervention consists of 24 weeks of systematic
computerized cognitive training, 4 hours per week, plus aerobic exercise, 150 minutes per
week. The Cognitive Training Intervention includes the same systematic cognitive training.
The first 12 weeks involve neurocognitive training, using training exercises from Posit
Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit
Science SocialVille modules. Aerobic exercise occurs as two 45-minute sessions at the clinic
and two 30-minute sessions at home weekly. Intensity of aerobic exercise is tailored to
maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
A weekly one-hour Bridging Skills Group with other members of the treatment condition is
designed to aid generalization of training to everyday life situations. The immediate target
is brain-derived neurotrophic factor. The primary treatment outcomes are overall cognitive
deficit level and global functioning level.

Inclusion Criteria:

1. a first episode of a psychotic illness that began within the past two years;

2. a diagnosis by DSM-5 of schizophrenia, schizoaffective disorder, mainly depressed
type, or schizophreniform disorder;

3. sufficient acculturation and fluency in the English language to avoid invalidating
research measures; and

4. residence likely to be within commuting distance of the UCLA Aftercare Research
Program.

Exclusion Criteria:

1. inability to participate in aerobic exercise;

2. evidence of a known neurological disorder (e.g., epilepsy) or significant head injury;

3. evidence of moderate or severe alcohol or substance use disorder within the six months
prior to the first episode or evidence that substance abuse triggered the psychotic
episode or makes the schizophrenia diagnosis ambiguous; or

4. mental retardation, i.e. estimated premorbid IQ less than 70.
We found this trial at
1
site
Los Angeles, California 90095
310-825-4321
Principal Investigator: Keith H Nuechterlein, Ph.D.
Phone: 310-206-3142
University of California at Los Angeles The University of California, Los Angeles (UCLA) is an...
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials